Gatifloxacin Carboxyclic Acid Ethyl Ester CAS 112811-71-9 Purity >99.0% (HPLC)

Ethyl 1-Cyclopropyl-6,7-Difluoro-1,4-Dihydro-8-Methoxy-4-Oxo-3-Quinolinecarboxylate (Gatifloxacin Carboxyclic Acid Ethyl Ester) (CAS: 112811-71-9) is an Intermediate of Gatifloxacin (CAS: 112811-59-3) / Moxifloxacin Hydrochloride (CAS: 186826-86-8).
Gatifloxacin is a fourth-generation fluoroquinolone belonging to the racemic group of 8-methofluoroquinolones, with a broad spectrum of anti-gram-negative and positive microorganisms and activity, by the Japanese Xinglin Pharmaceutical Co., Ltd. for the first time successfully developed, the R-and S-enantiomers of the same antibacterial activity, by inhibiting the bacterial DNA gyrase and topoisomerase IV, which inhibit bacterial DNA replication, transcription and repair process to work, has a strong antibacterial effect on a variety of bacteria, it has a good effect on respiratory system infection and reproductive system infection, and is one of the representatives of the "Respiratory fluoroquinolones" drugs that have grown rapidly in recent years. Clinical mainly for the treatment of a variety of mild to moderate infectious diseases caused by sensitive pathogens, including: acute exacerbation of chronic bronchitis, acute sinusitis, Community Acquired Pneumonia, simple urinary tract infection (cystitis) and complex urinary tract infection, cystitis, acute Pyelonephritis and infections of the urethra, cervix, rectum caused by Neisseria gonorrhoeae.
Moxifloxacin Hydrochloride is a fluoroquinolone antibiotic developed by Bayer Pharmaceuticals in Germany. Its mechanism of action and in vitro antibacterial spectrum are similar to other fluoroquinolone drugs, but its antibacterial activity against gram-positive bacteria and anaerobic bacteria is similar to that of travaxacin (trovafloxacin), which is better than some old varieties. Compared with other fluoroquinolones, Gram-positive bacteria resistant to this product are few or very slow. Cross-resistant bacteria with other fluoroquinolones have been found in Gram-negative bacteria and Enterococcus. However, this product is at least effective for staphylococcus aureus isolates grlA,grlB,gyrA or gyrB. This product can inhibit ciprofloxacin-resistant staphylococcus aureus at 0.5~2 mg/L, and is ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin in descending order according to MIC.